• Explore /
  • Poster
  • / A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).

A multicenter, phase II study of soluble LAG-3 (Eftilagimod Alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).

Abstract Poster

Authors

Julio Peguero

Julio Antonio Peguero

Oncology Consultants PA, Department of Research, Houston, TX

Julio Antonio Peguero , Pawan Bajaj , Enric Carcereny , Timothy Dudley Clay , Bernard Doger , Enriqueta Felip , Matthew Krebs , Martin Forster , Santiago Ponce Aix , Patricia Roxburgh , Frederic Triebel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

03625323

Citation

J Clin Oncol 37, 2019 (suppl; abstr TPS2667)

DOI

10.1200/JCO.2019.37.15_suppl.TPS2667

Abstract #

TPS2667

Poster Bd #

299b

Abstract Disclosures

Similar Posters

First Author: Bernard Doger de Spéville

First Author: Enriqueta Felip

First Author: Nicholas Coupe

First Author: Timothy Jay Price